137 filings
8-K
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
SYRE
Spyre Therapeutics Inc.
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
SYRE
Spyre Therapeutics Inc.
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
SYRE
Spyre Therapeutics Inc.
18 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm
8-K
SYRE
Spyre Therapeutics Inc.
8 Dec 23
Spyre Therapeutics Announces $180 Million Private Placement
8:45am
8-K
sir9vvqhnbvyn16u53s
28 Nov 23
Appoints CEO and Additional Directors, and Expands Leadership Team to
7:33am
8-K
qnsz2e1ksbzc25 gz
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
8:45pm
8-K
1m5i1yci9dwmfod40
15 Nov 23
Other Events
5:14pm
8-K
mrieq5o1
9 Nov 23
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
0njbi
24 Oct 23
Regulation FD Disclosure
9:00am
8-K
xcsguh9z
10 Oct 23
Report of Independent Registered Public Accounting Firm
12:00am
8-K
xbjy7oudp3m2
5 Oct 23
Entry into a Material Definitive Agreement
5:13pm
8-K
ri3ophs43b3yz62wq
25 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
wvkve4n
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
8-K
hv5bdg3q6m0
5 Sep 23
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
7:06am
8-K
mbn0d1jd
11 Aug 23
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
7:02am
8-K
6x7d8 yjisn2nu4
11 Aug 23
Termination of a Material Definitive Agreement
7:01am
8-K
g112 afzhj
27 Jul 23
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
7:01am
8-K
dp6smbydj
14 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
hdviu9piyix8rlf
23 Jun 23
Entry into a Material Definitive Agreement
9:16am